GlassScriptPhysician profile
Brittany Malabanan
NPI 1619635216
$1,856.82
in general payments reported to CMS, 2019-2025
18 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2024: $1,323 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $16.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.50 |
| Education | $16.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $298.47 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $261.22 | 2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $210.16 | 2024-2025 | |
| Ardelyx, INC. | $208.82 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $149.63 | 2024 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $111.90 | 2022 | |
| Amgen INC. | $108.13 | 2022-2025 | Aranesp, Tavneos, Parsabiv |
| Lilly USA, LLC | $81.63 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $78.34 | 2024-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $73.43 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $66.07 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.76 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $47.73 | 2024 | |
| Fresenius USA Marketing, INC. | $24.88 | 2024 | Velphoro |
| Baxter Healthcare | $23.49 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.68 | 2024 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2024 | Crysvita |
| Nuwellis, INC. | $16.04 | 2024 | Aquadex Smartflow Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Malabanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.